Testing effectiveness (Phase 2)Looking for participantsNCT06930651
What this trial is testing
A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies
Who this might be right for
Myeloid Malignancies
M.D. Anderson Cancer Center 42